1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Physician Views: How comfortable are doctors with the commercial use of gene therapy?

Physician Views: How comfortable are doctors with the commercial use of gene therapy?

  • March 2015
  • ID: 3509576
  • Format: PDF
  • By Firstword Pharma

Summary






Gene therapy has been around for decades, yet in a sense the concept has recently been made to feel new again thanks to some notable breakthroughs and milestones, not least of which was the European marketing approval for uniQure and Chiesi’s Glybera (alipogene tiparvovec) issued in late 2012 – the first-ever for a gene therapy in the Western world.

In the early days, gene therapy engendered high hopes as the thought of replacing non-functional genes with working versions sounded like an elegant, straight forward means for treating all manner of disease. In practice, however, the scientific complexities of designing and delivering the agents turned out to be far more difficult than initially envisioned, while serious safety questions slowed progress following events like the death of Jesse Gelsinger, who died in 1999 just weeks after receiving an experimental gene therapy in a clinical trial being conducted by the University of Pennsylvania.

The field has come a long way in the intervening years thanks to advances in the basic understanding of the downstream impact of replacing or modifying a gene sequence, along with significant improvements in the vectors used to safely and consistently deliver gene therapies to the target tissues. What’s more, clinicians working on product candidates have improved the design and conduct of studies in an effort to avoid incidents like the Gelsinger tragedy that cast a pall over the entire industry.
As for notable milestones, the first commercially approved gene therapy was developed by Shenzhen SiBiono GeneTech, which received the go-ahead from China’s health authority in 2003 to market Gendicine for use in treating head and neck cancer. A different product from Intrexon called Advexin that was engineered to express the same p53 gene was subsequently rejected by the FDA.

The biggest watershed moment for the field is undoubtedly the approval of Glybera, which is now commercially available in Europe for a rare inherited disorder called lipoprotein lipase deficiency (LPLD), while more recently companies like bluebird bio and Spark Therapeutics generated impressive clinical data with programmes of their own. These and other events have generated useful momentum for the entire field as additional gene therapy products continue to make their way into and through the clinic. The success has in turn generated renewed interest from both private and public equity investors as well as pharmaceutical companies, such as Bayer and Sanofi, which have willingly provided much-needed resources to companies working in the field in the form of financing and partnerships, helping to drive what could turn out to be a virtuous circle of success.








But what impact has the success of various gene therapies in clinical studies had on the sentiment among doctors, and how widespread has its acceptance as a therapeutic modality become in the decade and half since critical safety issues first emerged? To gain better understanding about the views of doctors on the potential of gene therapy, FirstWord PLUS is polling US- and EU5-based endocrinologists, haematologists, neurologists and ophthalmologists, asking them…




Gene therapy has not revolutionised the field of medicine the way some predicted it might decades ago but the science has, after many fits and starts, gained some long-anticipated momentum recently thanks to several exciting clinical readouts and the EU commercial launch of Glybera from uniQure and Chiesi – the first-ever for a gene therapy in the US or Europe. In general, how would you describe your sentiment towards gene therapy?
What are your thoughts about the long-term safety and how might these affect your prescribing habits once a gene therapy?
What is the biggest challenge facing widespread adoption of a gene therapy?
Glybera, a gene therapy for lipoprotein lipase deficiency, was recently launched in Germany at a price of more than 1 million euros ($1.1 million). How concerned are you that gene therapies like this may prove cost prohibitive?
Now that a gene therapy is approved in Europe and several heading towards marketing submissions in the next couple years, do you believe the field has reached a tipping point where clinical and regulatory success stories will begin emerging more rapidly?





Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2019

Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2019, provides ...

Global Gene Therapy Partnering Terms and Agreements 2014 to 2019

Global Gene Therapy Partnering Terms and Agreements 2014 to 2019

  • $ 2995
  • December 2019

The Global Gene Therapy Partnering Agreements 2014-2019 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.Trends ...

Primary Immune Deficiency (PID) - Pipeline Review, H2 2019

Primary Immune Deficiency (PID) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Primary Immune Deficiency (PID) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H2 2019, provides an ...


ref:plp2015

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on